Peptide Therapy: The Complete Guide to BPC-157, Semaglutide, and the Most Popular Protocols in 2026

This guide is for education, not medical or legal advice. Peptide rules are changing fast in 2026 — always confirm the current status of any peptide with a licensed prescriber and pharmacy before starting.

Peptide therapy has gone from a niche corner of anti-aging medicine to one of the most-searched topics in wellness — driven largely by the explosion of GLP-1 weight-loss drugs like Ozempic and a wave of "recovery" and "longevity" peptides marketed by med spas and telehealth clinics. But the category is also one of the most confusing and fastest-changing areas of medicine, where genuinely FDA-approved drugs sit on the same menu as unapproved research chemicals.

This guide explains what peptides actually are, profiles the eight most popular peptides in 2026, lays out the current regulatory landscape, and shows you how to tell a legitimate provider from a gray-market seller.

What peptides are and how they work

Peptides are short chains of amino acids — the same building blocks that make up proteins, just much smaller. Your body produces thousands of them naturally, and many act as chemical messengers: they tell cells to release a hormone, repair tissue, calm inflammation, or regulate appetite. Because peptides are small and highly specific, they can bind to particular receptors and trigger targeted effects rather than acting on the whole body at once.

Therapeutic peptides aim to copy or amplify these natural signals. Some are well-studied, FDA-approved medications — the GLP-1 drugs used for diabetes and weight loss are the headline example. Many others sold in the wellness world are not approved drugs. They are either prepared by compounding pharmacies under a prescription, or sold online as "research-use-only" chemicals never intended for human use. That distinction is the single most important thing to understand: an FDA-approved peptide has been tested for safety and effectiveness in large human trials, while a research-grade peptide has not, and its purity and dosing are not guaranteed.

How peptide therapy is taken

Most therapeutic peptides are given by subcutaneous injection — a small shot into the fat just under the skin, usually self-administered at home with a tiny insulin-style needle. The GLP-1 drugs (semaglutide, tirzepatide) are weekly subcutaneous injections delivered by prefilled pens, and semaglutide also comes as a daily oral tablet (Rybelsus). Growth-hormone peptides such as sermorelin, CJC-1295, and ipamorelin are typically injected at night, because that mirrors the body's natural growth-hormone pulse during sleep. Recovery peptides like BPC-157 are usually injected subcutaneously, sometimes near the area being treated. NAD+, the outlier, is delivered mainly by slow IV infusion at a clinic, though oral precursors and nasal sprays exist. Whatever the route, reconstituting powder, measuring the dose, and injecting safely are exactly the steps where a licensed prescriber and pharmacy matter most — dosing and sterility errors are among the most common problems with self-sourced peptides.

The 8 most popular peptides in 2026

A quick reference, then the details:

1. Semaglutide (Ozempic, Wegovy, Rybelsus)

Semaglutide is a GLP-1 receptor agonist — and it is the peptide that brought the whole category into the mainstream. It mimics the gut hormone GLP-1 to boost insulin release, slow stomach emptying, and reduce appetite by acting on the brain's hunger centers. It is fully FDA-approved: Ozempic for type 2 diabetes (2017), Wegovy for chronic weight management (2021) and for reducing cardiovascular risk in adults with obesity (March 2024). Thanks to manufacturer self-pay programs, cash prices have fallen to roughly $199–$499/month depending on dose, well below the old $1,000+ list price. Caveat: it works, but it carries real GI side effects (nausea, occasional gallbladder or pancreatitis risk), and weight tends to return if you stop — it is generally a long-term treatment.

2. Tirzepatide (Mounjaro, Zepbound)

Tirzepatide is a dual GIP/GLP-1 receptor agonist — it hits two gut-hormone receptors at once, which often produces greater weight loss than GLP-1-only drugs. It is FDA-approved: Mounjaro for diabetes (2022), Zepbound for weight loss (2023), and Zepbound became the first drug approved for moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024). Eli Lilly's self-pay vials run roughly $299–$449/month. Caveat: same GI side-effect profile as semaglutide, and long-term use is typically required to maintain results.

3. Sermorelin

Sermorelin is a growth-hormone-releasing hormone (GHRH) analog that prompts your pituitary gland to release more of your own growth hormone — a gentler, more "natural-rhythm" approach than injecting growth hormone directly. It has an unusual history: it was an FDA-approved drug (brand name Geref) before the manufacturer discontinued it in 2008 for business reasons, not safety. Today it exists only as a compounded product, but because of that prior approval it has the clearest legal footing of the GH-type peptides. Cost runs about $96–$400/month. Caveat: the compounded product is not FDA-approved, and modern anti-aging uses are off-label without large outcome trials.

4. BPC-157

BPC-157 ("Body Protection Compound") is a synthetic peptide derived from a protein found in stomach juice, marketed unofficially for tendon, ligament, gut, and joint recovery. The proposed mechanism — promoting blood-vessel growth and modulating growth factors — comes almost entirely from animal and cell studies, not human trials. It is not FDA-approved. The FDA placed it in the "Category 2" do-not-compound list in 2023, then removed it from that list in 2026 — but removal is not approval. It now sits in a regulatory gray zone pending an advisory-committee review. Most BPC-157 sold online is labeled "research use only." Cost ranges from ~$30–$120 per vial (research-grade) to ~$90–$650/month through supervised clinic programs. Caveat: the evidence in humans is essentially nonexistent, and long-term safety is unknown.

5. TB-500 (Thymosin Beta-4 fragment)

TB-500 is a synthetic fragment of Thymosin Beta-4, a protein involved in cell repair, promoted (alongside BPC-157) for injury recovery and inflammation. Like BPC-157, the evidence is overwhelmingly from animal models. It is not FDA-approved, was on the same Category 2 list, and is overwhelmingly sold as a "research chemical." It also appears on the World Anti-Doping Agency's banned list. Caveat: this is research-grade material, not a medicine — treat any human-use marketing with skepticism.

6 & 7. CJC-1295 and Ipamorelin

These two are almost always sold together as a "growth hormone" stack for anti-aging, recovery, and body composition. CJC-1295 is a GHRH analog and ipamorelin is a growth-hormone secretagogue that mimics ghrelin; together they prompt the pituitary to release growth hormone in pulses. A clinic stack typically runs $300–$600/month. Neither is FDA-approved. Both were removed from the Category 2 list in 2024, but the FDA's advisory committee recommended against adding them to the approved compounding list, citing safety concerns — so they remain in legal limbo and are largely sold research-grade. Caveat: artificially raising growth hormone carries real risks (fluid retention, insulin resistance, possible cardiovascular effects), and human safety data are sparse.

8. NAD+ (the "peptide connection")

NAD+ is the odd one out: it is not actually a peptide — it is a coenzyme (a dinucleotide) found in every cell, central to energy production and DNA repair. It is grouped with peptides purely because clinics sell both under the same "longevity / cellular optimization" banner, often side by side at IV bars. It is delivered mainly as an IV infusion ($250–$1,000 per session). It is not FDA-approved for any wellness use. Caveat: rigorous human trials showing IV NAD+ delivers anti-aging benefits essentially do not exist; oral precursors (NMN/NR) have slightly more — though still preliminary — data.

Who considers peptide therapy

Peptide therapy attracts a wide range of people. The GLP-1 drugs are used by adults managing type 2 diabetes or obesity, often after diet and exercise alone have stalled. Growth-hormone and recovery peptides tend to draw athletes, active adults, and people interested in anti-aging or "longevity" optimization. NAD+ appeals to those chasing energy and cellular-health claims. What unites the legitimate use cases is medical oversight — a prescriber who confirms the therapy is appropriate, screens for contraindications, and monitors your results over time. Peptide therapy is generally not appropriate for people who are pregnant or breastfeeding, those with active or a history of cancer (some peptides influence cell growth), or anyone hoping for a quick fix with no lifestyle change behind it. If a peptide is being sold to you as a miracle with no questions asked, that is a signal to slow down — not speed up.

The 2026 regulatory landscape: FDA compounding rules

The biggest story in peptides right now is the end of mass-market compounded GLP-1s. During the 2022–2024 shortage, federal law let pharmacies legally "compound" (make their own copies of) semaglutide and tirzepatide. That window has closed:

• The tirzepatide shortage was declared resolved in October 2024; compounding enforcement discretion ended in February–March 2025.
• The semaglutide shortage was declared resolved in February 2025; enforcement discretion ended in April–May 2025.
• Industry groups sued to block the deadlines, but the courts denied the injunctions, so they held.

A drug can normally only be mass-compounded while it is officially in shortage. With both shortages resolved, routine "compounded semaglutide/tirzepatide" subscriptions are no longer permitted as before — compounding is now limited to narrow, patient-specific exceptions (for example, a documented allergy to an inactive ingredient in the brand drug). Being cheaper than the brand is not a valid reason. In April 2026, the FDA went further and proposed to permanently exclude semaglutide, tirzepatide, and liraglutide from bulk 503B compounding, opening public comment through June 2026. The direction is clearly toward closing the door for good.

What this means for you: if a website is still selling cheap "compounded semaglutide" as a routine monthly subscription in 2026, treat it as a red flag. Legitimate access now generally means the brand-name FDA-approved drug or a genuinely individualized compound with a documented clinical reason.

For the "wellness" peptides, the picture is murkier. BPC-157, TB-500, and several others were removed from the FDA's Category 2 "do-not-compound" list in 2026 — but, crucially, removal from Category 2 is not approval. It simply moves them from an explicit do-not-compound bucket into an undecided gray zone, pending an advisory-committee review. Anyone telling you BPC-157 is now "clearly legal" is overstating it. Among the growth-hormone peptides, only tesamorelin (Egrifta) is FDA-approved, and only for a narrow HIV-related indication; sermorelin is compounded-only with the strongest legal footing, while CJC-1295 and ipamorelin remain contested.

Safety considerations and red flags

The single biggest danger in this space is the "research chemical" gray market. A huge volume of peptides is sold online by vendors who label their products "for research use only / not for human consumption" — a deliberate loophole to dodge drug regulation. The FDA considers these unapproved new drugs sold illegally and has issued warning letters to such sellers. The concrete risks:

• No purity, identity, or sterility guarantees. Research-grade vials may contain the wrong dose, contaminants, or a different substance entirely. Injecting non-sterile product risks infection.
• No dosing safety net. You are self-dosing an unstudied compound with no pharmacist or prescriber checking your technique, interactions, or contraindications.
• Counterfeit and illegally imported ingredients, often from unnamed overseas labs with no certificate of analysis.
• Limited human safety data for many wellness peptides, with theoretical concerns around cell growth and immune reactions.

Walk away from any seller that: labels products "research use only," requires no prescription, involves no licensed prescriber, prices implausibly low, ships from overseas, can't provide a certificate of analysis, or claims something is "FDA-approved" when it isn't (BPC-157, CJC-1295, and ipamorelin are not).

Compounding pharmacy vs telehealth vs in-person clinic

These three terms overlap but describe different layers of care:

• Compounding pharmacy (503A or 503B) — who makes the medication. A 503A pharmacy compounds for a specific patient with a prescription; a 503B "outsourcing facility" makes larger batches under stricter FDA manufacturing standards. Compounded drugs are not FDA-approved, and quality varies between pharmacies, so ask which one fills your prescription and verify its license with the state board.
• Telehealth provider — how you get the prescription. An online prescriber, often paired with a partner pharmacy that ships to you. Convenient and often cheaper, but the quality of the medical evaluation varies wildly — some are rubber-stamp questionnaire mills. Make sure there is a real, named, licensed prescriber and a named US pharmacy.
• In-person clinic (med spa / longevity clinic) — where you are seen. Offers face-to-face evaluation, labs, and supervised dosing, which makes monitoring easier — but it is more expensive, and some clinics push aggressive, evidence-thin peptide menus.

The key distinction: a gray-market website is none of these — no prescriber, no licensed pharmacy, no oversight. Legitimate care always has a licensed prescriber and a licensed US pharmacy somewhere in the chain.

How to find a legitimate provider

Before starting any peptide, look for all of the following:

• A licensed prescriber (MD, DO, NP, or PA) who evaluates you, takes a history, and writes an individual prescription — not just a checkout button.
• A US-licensed compounding pharmacy (503A) or FDA-registered 503B facility dispensing the product. Ask for the name and verify it with the state board of pharmacy.
• Bloodwork and screening before and during therapy — for growth-hormone peptides, that includes baseline labs and IGF-1 monitoring.
• Transparency: a good provider will tell you plainly that a peptide is compounded and not FDA-approved, explain the (often thin) evidence honestly, and disclose side effects.
• Ongoing follow-up, not a one-time anonymous sale.
• Honesty about the law — a trustworthy provider in 2026 acknowledges that peptides like BPC-157, CJC-1295, and ipamorelin sit in a contested legal space, and that routine GLP-1 compounding is now restricted.

The bottom line

Peptide therapy in 2026 spans a huge range of legitimacy. On one end are semaglutide and tirzepatide — rigorously tested, FDA-approved medications with strong evidence. On the other are research-grade peptides with little to no human data, sold through a gray market with real safety risks. The rules are changing month to month, especially for compounded GLP-1s and BPC-157. The safest path is the same one good medicine always recommends: work with a licensed prescriber and a licensed US pharmacy, insist on transparency, and be skeptical of anything that sounds too easy, too cheap, or too good to be true.

Sources: U.S. Food & Drug Administration (compounding policy statements, bulk-substance lists, and GLP-1 approval announcements); the Federal Register (sermorelin/Geref approval history); USADA and the U.S. Department of Defense's Operation Supplement Safety (BPC-157 status); and analyses from Alston & Bird, Epstein Becker Green, Frier Levitt, and Pharmacy Times on the 2025–2026 compounding rules. Cost figures reflect 2025–2026 manufacturer self-pay programs and clinic price ranges and vary by location and provider.